

## Adherium agreement signed with Dulcian Health for US remote patient monitoring

**Melbourne, Australia – 9 September 2022:** Adherium Limited ("Adherium" or "the Company"; ASX: ADR), a leader in respiratory eHealth, remote patient monitoring and data management solutions, is pleased to announce a partnership agreement with Dulcian Health ("Dulcian") to deploy the Hailie® platform enabling doctors and medical groups in the US to access reimbursement for remote monitoring of patients prescribed Asthma and COPD medications.

"We are eager to be partnering with Dulcian to include Adherium's Hailie sensors and data solution in its product offering to their current customer base and to jointly grow sales into more medical practices. This agreement marks another important step in the execution of the US commercial strategy with remote patient monitoring companies as a key channel in our go-to-market strategy. With our sophisticated devices and Dulcian's integrated platform, we are well positioned to advance patient care by bringing new solutions to doctors and their patients", said Adherium Chief Executive Officer, Rick Legleiter.

Focused on developing software that adds functionality to electronic health record (EHR) systems for over 20 years, Dulcian is a leader in Chronic Care Management (CCM) for physician practices in the US. Dulcian's innovative technology collects data already stored in the patient's EHR system and blends it with additional data to automatically build a Medicare-compliant care plan.

CCM services consist of establishing, implementing, revising, or monitoring a care plan for Medicare beneficiaries with two or more chronic conditions. Over 5% of CCM code claims are denied by Medicare and Dulcian's solution provides appropriate documentation and compliance tracking to minimise missed opportunities for physician practices to be reimbursed for their services.

As an extension, the Dulcian software accurately captures all clinical staff time spent performing non-face-to-face care activities, billable under CPT codes for care management services provided in CCM, Remote Physiologic Monitoring (RPM), and Remote Therapeutic Monitoring (RTM) programs. Dulcian's CCM platform will be

adherium

adapted to include RPM and RTM, and will leverage the inhalation data and physiological parameters generated by Adherium's next generation Hailie devices for

an initial one year term.

Dr Paul Dorsey, Chief Executive Officer of Dulcian Health, commented: "Dulcian

Health is very pleased to be partnering with Adherium. Digital inhalers provide

extraordinary health benefits to patients and help guide practitioners in their treatment

of respiratory diseases. Dulcian will work closely with Adherium to address how

providers can practically and meaningfully use the data generated from the digital

inhalers to improve patient care."

Respiratory diseases pose a major public health problem and are among the top

leading causes of death worldwide. Adherium's mission is to enhance healthcare

outcomes by improving patient quality of life of as the Company continues to build its

business with best-in-class partners.

-ENDS-

**About Adherium (ASX: ADR)** 

Adherium is a provider of integrated digital health solutions and a worldwide leader in

connected respiratory medical devices, with more than 180,000 sold globally.

Adherium's Hailie® platform solution provides clinicians, healthcare providers and

patients access to remotely monitor medication usage parameters and adherence,

supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and

sharing of health data via mobile and desktop apps, Software Development Kit (SDK)

and Application Programming Interface (API) integration tools, and Adherium's own

broad range of sensors connected to respiratory medications. Adherium's Hailie®

solution is designed to provide visibility to healthcare providers of medication use history

to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com



This ASX announcement was approved and authorised for release by the Board of Adherium.

**Enquiries:** WE Communications

WE-AUAdherium@we-worldwide.com

Data source for 5% claims denied: Use of Chronic Care Management Among Primary Care Clinicians - PMC (nih.gov) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7489968/